Your browser doesn't support javascript.
loading
Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more.
Wang, Zhi-Bin; Liu, Dan; Lei, Guang; Liu, Zhao-Qian; Wu, Nayiyuan; Wang, Jing.
Afiliação
  • Wang ZB; Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
  • Liu D; Public Service Platform of Tumor Organoids Technology, Hunan Gynecological Tumor Clinical Research Center, Changsha, Hunan, China.
  • Lei G; Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Liu ZQ; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Wu N; Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Wang J; Institute of Clinical Pharmacology, Engineering Research Center for applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, Hunan, China.
Front Pharmacol ; 14: 1222209, 2023.
Article em En | MEDLINE | ID: mdl-37361211
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2023 Tipo de documento: Article